|
Published by: BCC Research
Published: Jan. 1, 2004 - 184 Pages
Table of Contents
Introduction
Study Goals And Objectives
Scope Of Study
Methodology And Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Disclaimer
Executive Summary
Summary Table:
Market Size Of Substance Abuse Treatments And Diagnostics Revenues At U.S. Manufacturer Sales Levels, Through 2008 ($ Millions)
Summary Figure:
Market Size Of Substance Abuse Treatments And Diagnostics Revenues At U.S. Manufacturer Sales Levels, 2001-2008 ($ Millions)
Industry Overview
History Of Substance Abuse
Overview Of Substance Abuse
Models Of Addiction
Addiction Theories
Biological Theories
Psychological Theories
Sociocultural Theories
Patterns Of Substance Abuse
Risk Factors
Addictive Process
Demographic Trends
Tobacco Use
Figure 1 Past Month Tobacco Use Among Persons Aged 12 Or Older By Type Of Tobacco Use In The U.S., Estimated June 2003 (Population In Millions)
Age
Figure 2 Past Month Tobacco Use Among Persons Aged 12 Or Older In The U.S., Estimated June 2003 (%)
Gender
Figure 3 Past Month Tobacco Use For Males And Females Aged 12 Or Older In The U.S., Estimated 2003 (%)
Pregnant Women
Figure 4 Past Month Tobacco Use For Pregnant And Non-Pregnant Women Aged 15 To 44 In The U.S., Estimated June 2003 (%)
Race/Ethnicity
Figure 5 Past Month Tobacco Use Among Persons Aged 12 Or Older By Race/Ethnicity In The U.S., Estimated June 2003 (%)
Education
Figure 6 Past Month Tobacco Use Among Persons Aged 18 Or Older By Education Level In The Use, Estimated June 2003 (%)
College Students
Figure 7 Past Month Tobacco Use Enrollment Status For College Students Aged 18 To 22 In The U.S., Estimated June 2003 (%)
Employment
Figure 8 Past Month Tobacco Use By Employment Status 18 And Older In The U.S., Estimated June 2003 (%)
Geographic Area
Figure 9 Past Month Tobacco Use For Geographic Region Based On Population Density Ages 12 Or Older In The U.S., Estimated June 2003 (%)
Frequency Of Cigarette Use
Figure 10 Frequency Of Tobacco Use Among Current Smokers By Age In The U.S., Estimated June 2003 (%)
Association Of Tobacco Use With Illicit Drug And Alcohol Use
Figure 11 Past Month Illicit Drug, Binge Alcohol, And Heavy Alcohol Use Among Smokers And Nonsmokers Aged 12 Or Older In The U.S., Estimated June 2003 (%)
Usual Brand Of Cigarettes Smoked
Youth Access To Cigarettes In The Past Month
Specialty Cigarettes (Bidi And Clove Cigarettes)
Alcohol Use
Figure 12 Past Month Alcohol Use Among Persons Aged 12 Or Older By Frequency In The U.S., Estimated June 2003 (Population In Millions)
Age
Figure 13 Past Month Alcohol Use Among Persons By Age In The U.S., Estimated June 2003 (%)
Gender
Figure 14 Past Month Alcohol Use For Males And Females Age 12 Or Older In The U.S., Estimated June 2003 (%)
Pregnant Women
Figure 15 Past Month Alcohol Use For Pregnant And Non-Pregnant Women Aged 15 To 44 In The U.S., Estimated June 2003 (%)
Race/Ethnicity
Figure 16 Past Month Alcohol Use Among Persons Aged 12 Or Older By Race/Ethnicity In The U.S., Estimated June 2003 (%)
Education
Figure 17 Past Month Alcohol Use Among Persons Aged 18 Or Older By Education Level In The U.S., Estimated June 2003 (%)
College Students
Figure 18 Past Month Alcohol Use Enrollment Status For College Students Aged 18 To 22 In The U.S., Estimated June 2003 (%)
Employment
Figure 19 Past Month Alcohol Use By Employment Status 18 And Older In The U.S., Estimated June 2003 (%)
Geographic Area
Figure 20 Past Month Alcohol Use For Geographic Region Based On Population Density Ages 12 Or Older In The U.S., Estimated June 2003 (%)
Association With Illicit Drug And Tobacco Use
Figure 21 Past Month Illicit Drug And Tobacco Use Among Drinkers And Nondrinkers Aged 12 Or Older, Estimated June 2003 (%)
Driving Under The Influence Of Alcohol
Illicit Drug Use
Figure 22 Past Month Illicit Drug Use Among Persons Aged 12 Or Older By Type Of Drug In The U.S., Estimated June 2003 (Population In Millions)
Age
Figure 23 Past Month Illicit Drug Use By Age In The U.S., Estimated June 2003 (%)
Gender
Figure 24 Past Month Illicit Drug Use For Males And Females Aged 12 Or Older In The U.S., Estimated June 2003 (%)
Pregnant Women
Figure 25 Past Month Illicit Drug Use For Pregnant And Nonpregnant Women Aged 15 To 44 In The U.S., Estimated June 2003 (%)
Race/Ethnicity
Figure 26 Past Month Illicit Drug Use Among Persons Aged 12 Or Older By Race/Ethnicity In The U.S., Estimated June 2003 (%)
Education
Figure 27 Past Month Illicit Drug Use Among Persons Aged 18 Or Older By Education Level In The U.S., Estimated June 2003 (%)
College Students
Figure 28 Past Month Illicit Drug Use Enrollment Status For College Students Aged 18 To 22 In The U.S., Estimated June 2003 (%)
Employment
Figure 29 Past Month Illicit Drug Use By Employment Status 18 And Older In The U.S., Estimated June 2003 (%)
Geographic Area
Figure 30 Past Month Illicit Drug Use For Geographic Region Based On Population Density Ages 12 Or Older In The U.S., Estimated June 2003 (%)
Criminal Justice Populations
Figure 31 Past Year Illicit Drug Use By Parole And Probation Status Aged 18 Or Older In The U.S., Estimated 2003 (%)
Frequency Of Use
Figure 32 Frequency Of Illicit Drug Use Among Past Year Users Age 12 Or Older In The U.S., Estimated 2003 (%)
Association With Cigarette And Alcohol Use
Figure 33 Past Month Alcohol And Tobacco Use Among Illicit Drug Users And Non Illicit Drug Users Aged 12 Or Older In The U.S., Estimated June 2003 (%)
Driving Under The Influence Of Illicit Drugs
Figure 34 Past Year Frequency Of Driving Under The Influence Of Illicit Drugs, Ages 12 Or Older In The U.S., Estimated 2003 (Population In Millions)
Managed Care Impact
Reimbursement Issues
Economic Costs Of Substance Abuse
Table 1 Economic Costs To Society Of Drug Abuse, 1992-2002 ($ Millions)
Stumbling Blocks To Drug Abuse Treatment
New Avenues For Treatment Of Substance Abuse
Geriatric Substance Abuse
Regulatory Issues
Effects Of Poly Drug Abuse
Polydrug Use By Age
Primary And Secondary Use
Legislative Issues
State Law Revisions
Federal Law Revisions
Arizona Proposition 200
California Proposition 36
Federal Initiative
The Uninsured
Table 2 Top 10 Uninsured Principal Diagnoses In U.S. Hospitals, 2000
Treatment Facilities And Programs
Ownership Of Substance Abuse Facilities
Table 3 Number And Percentage Distribution Of Single And Multiple Modality Substance Abuse Treatment Facilities, 1999
Treatment Costs
Residential Rehabilitation Patterns
Culture
Antabuse
Basic Methods
Internet Sales Of Drugs
Online Drug Abuse Treatment
National Programs For Substance Abuse
Barriers To Market Entry
Nonacceptance Of Medical Models Of Addiction
Pharmaceutical Products
Stimulants
Nicotine
Characteristics
Effects Of Use
Complications
Therapeutic Management
Table 4 Smoking Cessation Products
Amphetamines
Characteristics
Effects Of Use
Complications
Therapeutic Management
Table 5 Amphetamine Abuse Treatments
Cocaine And Crack
Characteristics
Effects Of Use
Complications
Therapeutic Management
Table 6 Cocaine Abuse Treatments
Other Stimulants
Depressants
Sedatives-Hypnotics
Characteristics
Effects Of Use
Complications
Therapeutic Management
Alcohol
Characteristics
Effects Of Use
Complications
Therapeutic Management
Table 7 Alcohol Abuse Treatments
Opiates
Characteristics
Effects Of Use
Complications
Therapeutic Management
Methadone
Other Products
Table 8 Opiate Abuse Treatments
Hallucinogens
Cannabis
Characteristics
Effects Of Use
Complications
Therapeutic Management
Lysergic Acid Diethylamide, Dimethyltryptamine, Mescaline, And Related Substances
Characteristics
Effects Of Use
Therapeutic Management
Other Hallucinogens
Extent Of Use
Inhalants And Other Drugs Of Abuse
Gases, Solvents And Nitrites
Anabolic Steroids
Diagnostic Testing
Urine Testing
Saliva Testing
Blood Testing
Patch Testing
Hair Testing
Samhsa Positive Drug Test Guidelines
Table 9 Positive Drug Test Guidelines, 2003
Drug Testing Indexes
Table 10 Annual Drug Positivity Rates, 1988-2002 (%)
Table 11 Positivity Rates By Drug Category, 1999-2002 (%)
Point-Of-Care Substance Abuse Diagnostic Testing
Tobacco Testing
Table 12 Point-Of-Care Nicotine Diagnostic Test Products
Alcohol Testing
Table 13 Point Of Care Alcohol Diagnostic Test Products
Drug Testing
Abbot Diagnostics
Advantage Diagnostics
Alfa Scientific Designs
American Bio Medica
Bioscan Screening Systems
Biosite Diagnostics
Dade Behring
Medtox Scientific, Inc.
Orasure Technologies
Phamatech
Princeton Biomeditech
Psychemedics Corp.
Roche Diagnostics
Sun Biomedical
Worldwide Medical
Table 14 Point-Of-Care Drug Diagnostic Testing Products
Home Substance Abuse Diagnostic Testing
Tobacco Testing
Table 15 Nicotine Home Diagnostic Testing Products
Alcohol Testing
Table 16 Alcohol Home Diagnostic Testing Products
Drug Testing
Psychemedics
Dr. Brown's
American Medical Screening
Phamatech
Parents At Home
Advantage Diagnostics
Forefront Diagnostics
Princeton Biomeditech
Sun Biomedical Laboratories
Worldwide Medical
Table 17 Drug Home Diagnostic Testing Products
Market Size And Growth
Table 18 Market Size Of U.S. Addiction And Substance Abuse Treatments And Diagnostic Market Revenues At U.S. Manufacturer Sales Levels, Through 2008 ($ Millions)
Figure 35 Market Size Of U.S. Addiction And Substance Abuse Treatments And Diagnostic Market Revenues At U.S. Manufacturer Sales Levels, 2001-2008 ($ Millions)
Prescription And Over-The-Counter Pharmaceutical Treatments
Stimulants
Depressants
Hallucinogens
Table 19 Market Size Of U.S. Addiction And Substance Abuse Pharmaceutical Treatments By Type At U.S. Manufacturer Sales Levels, Through 2008 ($ Millions)
Figure 36 Market Size Of U.S. Addiction And Substance Abuse Pharmaceutical Treatments By Type At U.S. Manufacturer Sales Levels, 2001-2008 ($ Millions)
Diagnostic Testing
Table 20 Market Size Of Substance Abuse Diagnostics By Type At U.S. Manufacturer Sales Levels, Through 2008 ($ Millions)
Figure 37 Market Size Of Substance Abuse Diagnostics By Type At U.S. Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Research And Development
Goals
Areas Of Concentration
Industry Needs
Current Drugs In Clinical Trials
Alcohol Treatment
Opiate Treatment
General Addiction
Tobacco Treatment
Cocaine Treatment
Table 21 Substance Abuse Products In Development
Miscellaneous Substance Abuse Treatment Discoveries
Industry Structure
Market Leaders
Glaxosmithkline
Roxane Laboratories
Novartis
Reckitt Benckiser
Pfizer
Barr Laboratories
Psychemedics
Wyeth
Roche
Other Companies
Table 22 Total Manufacturer Market Share Of Substance Abuse Treatments And Diagnostics By Revenues At U.S. Manufacturer Sales Levels, Estimated 2003 ($ Millions, %)
Figure 38 Total Manufacturers Market Share Of Substance Abuse Treatments And Diagnostics At U.S. Manufacturer Sales Levels, Estimated 2003 (%)
Table 23 Total Manufacturers Market Share Of Substance Abuse Pharmaceutical Treatments By Revenues At U.S. Manufacturer Sales Levels, Estimated 2003 ($ Millions, %)
Figure 39 Total Manufacturers Market Share Of Substance Abuse Pharmaceutical Treatments At U.S. Manufacturer Sales Levels, Estimated 2003 (%)
Table 24 Total Manufacturers Market Share Of Substance Abuse Diagnostics By Revenues At U.S. Manufacturer Sales Levels, Estimated 2003 ($ Millions, %)
Figure 40 Total Manufacturers Market Share Of Substance Abuse Diagnostics By Revenues At U.S. Manufacturer Sales Levels, Estimated 2003 (%)
Industry Participants By Product Type
Table 25 Substance Abuse Pharmaceutical Treatment And Diagnostic Testing Manufacturers By Product Type, 2003
Market Analysis
Anti-Depressant Market
Additional Therapies
Opportunities
Company Profiles
Advantage Diagnostics
Barr Laboratories
Chematics
Drugabuse Sciences
Glaxosmithkline Plc
Novartis Pharmaceuticals Corp.
Odyssey Pharmaceuticals, Inc.
Pfizer, Inc.
Phamatech, Inc.
Psychemedics Corp.
Reckitt Benckiser Plc
Roxane Laboratories, Inc.
Sun Biomedical Laboratories, Inc.
Roche
Worldwide Medical Corp.
Wyeth
Appendices
Treatment Facility Admissions By State
Table 26 Number Of Admissions To Treatment Facilities By Primary Substance And State, Primary Substances
Table 27 Number Of Admissions To Treatment Facilities By Primary Substance And State, Secondary Substances
Table 28 Number Of Admissions To Treatment Facilities By Primary Substance And State, Other Substances
List Of Companies
AbstractThis BCC report details the complicated and frustrating world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption. Abuse of prescription drugs and alcohol places a heavy burden on health resources because of the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report along with up-and-coming products that may provide even better alternatives. Revenues are presented for 2000, 2001, 2002, and 2008. Revenues include both prescription and OTC products. Competitor market share will be presented for 2002.
Get Full Details About This Report >>
|
